{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:49:23Z","timestamp":1789152563869,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.waojou.2020.100462","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T21:10:32Z","timestamp":1600377032000},"page":"100462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9088-5214","authenticated-orcid":false,"given":"Claudia","family":"Crimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cacopardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Intravaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santi","family":"Nolasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzio","family":"Crimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.waojou.2020.100462_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.waojou.2020.100462_bib2","unstructured":"European Medicine Agency (Ema). https:\/\/www.ema.europa.eu\/en\/documents\/overview\/nucala-epar-medicine-overview_en.pdf Last accessed 25 november 2019."},{"issue":"5","key":"10.1016\/j.waojou.2020.100462_bib3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"9842","key":"10.1016\/j.waojou.2020.100462_bib4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe\u00a0eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.waojou.2020.100462_bib5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.waojou.2020.100462_bib6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.waojou.2020.100462_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/8da4be4b-2de1-4c51-9c40-0f49dc212579","article-title":"Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials","volume":"8","author":"Liu","year":"2013","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.waojou.2020.100462_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2796.2012.02559.x","article-title":"Chronic rhinosinusitis and asthma: novel understanding of the role of IgE 'above atopy'","volume":"272","author":"Bachert","year":"2012","journal-title":"J\u00a0Intern Med"},{"issue":"1","key":"10.1016\/j.waojou.2020.100462_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1465-9921-13-10","article-title":"Relationship between body composition, inflammation and lung function in overweight and obese asthma","volume":"13","author":"Scott","year":"2012","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.waojou.2020.100462_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/ACI.0000000000000492","article-title":"Bronchiectasis and asthma: a dangerous liaison?","volume":"19","author":"Crimi","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2020.100462_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/ers.11.34","article-title":"Asthma-related comorbidities","volume":"5","author":"Boulet","year":"2011","journal-title":"Expet Rev Respir Med"},{"issue":"5","key":"10.1016\/j.waojou.2020.100462_bib12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.waojou.2020.100462_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pupt.2014.01.005","article-title":"Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view","volume":"27","author":"Saturni","year":"2014","journal-title":"Pulm Pharmacol Therapeut"},{"key":"10.1016\/j.waojou.2020.100462_bib14","series-title":"Global Strategy for Asthma Management and Prevention","year":"2016"},{"issue":"6","key":"10.1016\/j.waojou.2020.100462_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.anai.2011.09.001","article-title":"Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria","volume":"107","author":"Korn","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.waojou.2020.100462_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"ATS\/ERS task force. Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.waojou.2020.100462_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.waojou.2020.100462_bib18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2020.100462_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2018.09.006","article-title":"Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study","volume":"53","author":"Pelaia","year":"2018","journal-title":"Pulm Pharmacol Therapeut"},{"key":"10.1016\/j.waojou.2020.100462_bib20","first-page":"1","article-title":"Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma","author":"Pertzov","year":"2019","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.waojou.2020.100462_bib21","doi-asserted-by":"crossref","first-page":"101836","DOI":"10.1016\/j.pupt.2019.101836","article-title":"One year of mepolizumab. Efficacy and safety in real-life in Italy","volume":"58","author":"Bagnasco","year":"2019","journal-title":"Pulm Pharmacol Therapeut"},{"issue":"12","key":"10.1016\/j.waojou.2020.100462_bib22","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/17476348.2019.1676734","article-title":"Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response","volume":"13","author":"Caminati","year":"2019","journal-title":"Expet Rev Respir Med"},{"key":"10.1016\/j.waojou.2020.100462_bib23","doi-asserted-by":"crossref","first-page":"212584","DOI":"10.7573\/dic.212584","article-title":"Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice","volume":"8","author":"Montero-P\u00e9rez","year":"2019","journal-title":"Drugs Context"},{"issue":"3 Suppl","key":"10.1016\/j.waojou.2020.100462_bib24","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2011.12.986","article-title":"Asthma outcomes: pulmonary physiology","volume":"129","author":"Tepper","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.waojou.2020.100462_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12890-018-0689-2","article-title":"Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response","volume":"18","author":"Drick","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"6","key":"10.1016\/j.waojou.2020.100462_bib26","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.waojou.2020.100462_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40413-018-0210-7","article-title":"The North-Western Italian experience with anti IL-5 therapy and comparison with regulatory trials","volume":"11","author":"Bagnasco","year":"2018","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.waojou.2020.100462_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/JAA.S196200","article-title":"Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab","volume":"12","author":"Carpagnano","year":"2019","journal-title":"J\u00a0Asthma Allergy"},{"issue":"1","key":"10.1016\/j.waojou.2020.100462_bib29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12890-019-0952-1","article-title":"Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis","volume":"19","author":"Numata","year":"2019","journal-title":"BMC Pulm Med"},{"issue":"7","key":"10.1016\/j.waojou.2020.100462_bib30","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1513\/AnnalsATS.201312-454OC","article-title":"Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma","volume":"11","author":"Ortega","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.waojou.2020.100462_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12931-019-1134-7","article-title":"Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight\/body mass index: meta-analysis of MENSA and MUSCA","volume":"20","author":"Albers","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.waojou.2020.100462_bib32","doi-asserted-by":"crossref","first-page":"105806","DOI":"10.1016\/j.rmed.2019.105806","article-title":"Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma","volume":"159","author":"Albers","year":"2019","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.waojou.2020.100462_bib33","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-2600(16)30103-5","article-title":"Severe eosinophilic asthma and mepolizumab","volume":"4","author":"Walsh","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.waojou.2020.100462_bib34","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/cea.13613","article-title":"Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype","volume":"50","author":"Pelaia","year":"2020","journal-title":"Clin Exp Allergy"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455120303653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455120303653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:42:23Z","timestamp":1761849743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455120303653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1939455120303653"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2020.100462","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.26.20112052","asserted-by":"object"}]},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2020.100462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"100462"}}